Journal article

HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes

Sophia S Wang, Mary Carrington, Sonja I Berndt, Susan L Slager, Paige M Bracci, Jenna Voutsinas, James R Cerhan, Karin E Smedby, Henrik Hjalgrim, Joseph Vijai, Lindsay M Morton, Roel Vermeulen, Ora Paltiel, Claire M Vajdic, Martha S Linet, Alexandra Nieters, Silvia de Sanjose, Wendy Cozen, Elizabeth E Brown, Jennifer Turner Show all

Cancer Research | AMER ASSOC CANCER RESEARCH | Published : 2018

Grants

Awarded by NIH


Awarded by U.S. Public Health Service from NCI, Department of Health and Human Services


Awarded by HuGeF (Human Genetics Foundation), Torino, Italy


Awarded by European Commission


Awarded by Spanish Ministry of Health


Awarded by Marato de TV3 Foundation


Awarded by Agencia de Gestio d'Ajuts Universitarisi de Recerca-Generalitat de Catalunya


Awarded by Federal Office for Radiation Protection


Awarded by Jose Carreras Leukemia Foundation


Awarded by German Federal Ministry for Education and Research


Awarded by MH CZ - DRO (MMCI)


Awarded by MEYS-NPS


Awarded by Frederick National Laboratory for Cancer Research


Awarded by National Center for Advancing Translational Science


Awarded by NCI-Specialized Programs of Research Excellence (SPORE) in Human Cancer


Awarded by NCI


Awarded by Italian Association for Cancer Research (AIRC)


Awarded by Regione Autonoma della Sardegna


Awarded by Australian NHMRC grants


Awarded by Lymphoma Foundation


Awarded by Barbara K. Lipman Lymphoma Research Fund


Awarded by Robert and Kate Niehaus Clinical Cancer Genetics Research Initiative


Awarded by Public Health Service


Awarded by Australian National Health and Medical Research Council


Awarded by National Institute of Environmental Health Sciences


Awarded by Swedish Cancer Society


Awarded by Stockholm County Council


Awarded by NCI, NIH


Awarded by NCI's Surveillance, Epidemiology, and End Results Program


Awarded by Centers for Disease Control and Prevention's National Program of Cancer Registries


Awarded by HCI Cancer Center



Funding Acknowledgements

This project was supported in part with funding from the NIH (R01CA179558 and R01CA33572).ATBC. The ATBC Study is supported by the Intramural Research Program of the U.S. NCI, NIH, and by U.S. Public Health Service contract HHSN261201500005C from the NCI, Department of Health and Human Services.CPS-II. The Cancer Prevention Study-II (CPS-II) Nutrition Cohort is supported by the American Cancer Society. Genotyping for all CPS-II samples were supported by the Intramural Research Program of the NIH, NCI, Division of Cancer Epidemiology and Genetics. The authors would also like to acknowledge the contribution to this study from central cancer registries supported through the Centers for Disease Control and Prevention National Program of Cancer Registries, and cancer registries supported by the NCI Surveillance Epidemiology and End Results program.EPIC. Coordinated Action (Contract # 006438, SP23-CT-2005-006438), HuGeF (Human Genetics Foundation), Torino, Italy; and Cancer Research UK.EpiLymph. European Commission (grant references QLK4-CT-2000-00422 and FOOD-CT-2006-023103); the Spanish Ministry of Health (grant references CIBERESP, PI11/01810, PI14/01219, RCESP C03/09, RTICESP C03/10 and RTIC RD06/0020/0095), the Marato de TV3 Foundation (grant reference 051210), the Agencia de Gestio d'Ajuts Universitarisi de Recerca-Generalitat de Catalunya (grant reference 2014SRG756) who had no role in the data collection, analysis or interpretation of the results; the NIH (contract NO1-CO-12400); the Compagnia di San Paolo-Programma Oncologia; the Federal Office for Radiation Protection grants StSch4261 and StSch4420, the Jose Carreras Leukemia Foundation grant DJCLS-R12/23, the German Federal Ministry for Education and Research (BMBF-01-EO-1303); the Health Research Board, Ireland and Cancer Research Ireland; Czech Republic supported by MH CZ - DRO (MMCI, 00209805) and MEYS-NPS I-LO1413; Fondation de France and Association de Recherche Contre le Cancer.FNLCR. This project has been funded in whole or in part with federal funds from the Frederick National Laboratory for Cancer Research, under Contract No. HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. This Research was supported in part by the Intramural Research Program of the NIH, Frederick National Lab, Center for Cancer Research.GEC/Mayo GWAS. NIH (CA118444, CA148690, and CA92153). Intramural Research Program of the NIH, NCI. Veterans Affairs Research Service. Data collection for Duke University was supported by a Leukemia and Lymphoma Society Career Development Award, the Bernstein Family Fund for Leukemia and Lymphoma Research, and the NIH (K08CA134919), National Center for Advancing Translational Science (UL1 TR000135).HPFS. The HPFS was supported in part by NIH grants CA167552, CA149445, and CA098122. We would like to thank the participants and staff of the Health Professionals Follow-up Study for their valuable contributions as well as the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WY. The authors assume full responsibility for analyses and interpretation of these data.Iowa-Mayo SPORE. NCI-Specialized Programs of Research Excellence (SPORE) in Human Cancer (P50 CA97274); NCI (P30 CA086862 and P30 CA15083); Henry J. Predolin Foundation.Italian GxE. Italian Association for Cancer Research (AIRC, Investigator Grant 11855) (PC); Fondazione Banco di Sardegna 2010-2012, and Regione Autonoma della Sardegna (LR7 CRP-59812/2012) (MGE).Mayo Clinic Case-Control. NIH (R01 CA92153) and NCI (P30 CA015083).MCCS. The Melbourne Collaborative Cohort Study recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was further supported by Australian NHMRC grants 209057, 251553, and 504711 and by recurrent funding and infrastructure provided by Cancer Council Victoria. The incidence of malignancy and their participants' vital status were ascertained through the Victorian Cancer Registry and the Australian Institute of Health and Welfare, including the National Death Index and the Australian Cancer Database.MSKCC. Geoffrey Beene Cancer Research Grant, Lymphoma Foundation (LF5541); Barbara K. Lipman Lymphoma Research Fund (74419); Robert and Kate Niehaus Clinical Cancer Genetics Research Initiative (57470); U01 HG007033; ENCODE; U01 HG007033.NCI-SEER. Intramural Research Program of the NCI, NIH, and Public Health Service (N01-PC-65064, N01-PC-67008, N01-PC-67009, N01-PC-67010, and N02-PC-71105).NHS. The NHS was supported in part by NIH grants CA186107, CA87969, CA49449, CA149445, and CA098122. We would like to thank the participants and staff of the Nurses' Health Study for their valuable contributions as well as the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WY. The authors assume full responsibility for analyses and interpretation of these data.NSW. NSW was supported by grants from the Australian National Health and Medical Research Council (ID990920), the Cancer Council NSW, and the University of Sydney Faculty of Medicine.NYU-WHS. NCI (R01 CA098661 and P30 CA016087) and the National Institute of Environmental Health Sciences (ES000260).PLCO. This research was supported by the Intramural Research Program of the NCI and by contracts from the Division of Cancer Prevention, NCI, NIH, and DHHS.SCALE. Swedish Cancer Society (2009/659). Stockholm County Council (20110209) and the Strategic Research Program in Epidemiology at Karolinska Institutet. Swedish Cancer Society grant (02 6661). NIH (5R01 CA69669-02); Plan Denmark.UCSF2. The UCSF studies were supported by the NCI, NIH, CA1046282 and CA154643. The collection of cancer incidence data used in this study was supported by the California Department of Health Services as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885; the NCI's Surveillance, Epidemiology, and End Results Program under contract HHSN261201000140C awarded to the Cancer Prevention Institute of California, contract HHSN261201000035C awarded to the University of Southern California, and contract HHSN261201000034C awarded to the Public Health Institute; and the Centers for Disease Control and Prevention's National Program of Cancer Registries, under agreement #1U58 DP000807-01 awarded to the Public Health Institute. The ideas and opinions expressed herein are those of the authors, and endorsement by the State of California, the California Department of Health Services, the NCI, or the Centers for Disease Control and Prevention or their contractors and subcontractors is not intended nor should be inferred.UTAH. NIH CA134674. Partial support for data collection at the Utah site was made possible by the Utah Population Database (UPDB) and the Utah Cancer Registry (UCR). Partial support for all datasets within the UPDB is provided by the Huntsman Cancer Institute (HCI) and the HCI Cancer Center Support grant, P30 CA42014. The UCR is supported in part by NIH contract HHSN261201000026C from the NCI SEER Program with additional support from the Utah State Department of Health and the University of Utah.YALE. NCI (CA62006 and CA165923).